January 25, 2022 -- NanoMosaic has signed a lease for a stand-alone building of 30,880 sq ft in Waltham, MA. NanoMosaic is a biotechnology company that pioneered nanoneedle (MosaicNeedle) technology detection for proteomics, genomics, and single-run experiment multiomics applications, alongside the development of assays for biomarker discovery and validation.
The company's new headquarters are strategically located in an emerging biotech hub just outside of Cambridge, MA, and Boston that will allow space for its rapidly growing biology, application development, software, manufacturing, and commercial teams. According to NanoMosaic, there is significant market demand for the Tessie system, which alleviates bottlenecks in proteomics analysis and enables first-of-its-kind protein interrogation and multiomics analysis within a single chip in one run.
NanoMosaic is rapidly hiring for -- and has listed -- open positions for experienced and ambitious life science researchers, as well as for commercial positions, as the company expands.
"The completion of the company's new headquarters will further enable the company's transition to a fully focused commercial entity as the custom designed and fully outfitted GMP manufacturing suite will bolster the company's business objectives," Joe Wilkinson, chief operating officer of NanoMosaic, said in a statement. "This expansion allows for large scale, vertically integrated manufacturing of the Tessie instrument, consumables and reagents."